-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Initiates Coverage On Evommune with Outperform Rating, Announces Price Target of $42

Benzinga·12/01/2025 12:30:20
Listen to the news
Leerink Partners analyst Thomas Smith initiates coverage on Evommune (NYSE:EVMN) with a Outperform rating and announces Price Target of $42.